Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention

Chinese Medical Journal

Volumn 125, Issue 4, 2012, Pages 631-638

  Tang, Fa Kuan ^a   Lin, Le Jian ^a   Hua, Ning ^a   Lu, Hong ^a   Qi, Zhi ^a   Tang, Xue Zheng ^a  

^a 309TH HOSPITAL OF PLA   (China)

Author keywords

Aspirin resistance; Cardiovascular ischemic events; Clopidogrel resistance; Percutaneous coronary intervention; Thrombelastograph

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC ACID DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BLEEDING; BLOOD SAMPLING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR ISCHEMIC DISEASE; CONTROLLED STUDY; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY STENT; DIABETES MELLITUS; DRUG INHIBITION; DRUG SENSITIVITY; FAMILY HISTORY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LEFT CORONARY ARTERY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RIGHT CORONARY ARTERY; RISK FACTOR; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; UNSTABLE ANGINA PECTORIS;

ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY; THROMBOSIS; TICLOPIDINE;

EID: 84857463174     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.04.014     Document Type: Article

References (33)

1. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 2006; 19: 439-448.
2. Cutlip DE, Baim DS, Ho KK, Popma JJ, Lansky AJ, Cohen DJ, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103: 1967-1971.
3. Orford JL, Lennon R, Melby S, Fasseas P, Bell MR, Rihal CS, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol 2002; 40: 1567-1572.
4. Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 2007; 71: 226-228.
5. Biondi-Zoccai GG, Agostoni P, Sangiorgi GM, Iakovou I, Antoniucci D, Grube E, et al. TRUE (Taxus in Real-Life Usage Evaluation) Study Investigators. Comparison of ticlopidine vs. clopidogrel in addition to aspirin after paclitaxel-eluting stent implantation: insights from the TRUE (Taxusin Real-life Usage Evaluation) Study. Int J Cardiol 2006; 108: 406-407.
6. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302.
7. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
8. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 2006; 4: 542-549.
9. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. J Am Coll Cardiol 2008; 51: 1404-1411.
10. Shim CY, Yoon SJ, Park S, Kim JS, Choi JR, Ko YG, et al. The clopidogrel resistance can be attenuated with triple antiplatelet therapy in patients undergoing drug-eluting stents implantation. Int J Cardiol 2009; 134: 351-355.
11. Kobayashi T, Tahara Y, Matsumoto M, Iguchi M, Sano H, Murayama T, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest Sep 2004; 114: 784-794.
12. Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest Jan 2001; 119 (1 Suppl): 39S-63S.
13. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 202-207.
14. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost Aug 2003; 1: 1710-1713.
15. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650-1655.
16. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, Steg PG, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48: 931-938.
17. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry U. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45: 1392-1396.
18. Buonamici P, Marcucci R, Migliorini A, Franco Gensini G, Santiniet A, Paniccia R, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007; 49: 2312-2317.
19. Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during theprocess of whole blood clotting as assessed by thromboelastography. J Thromb Haemost 2005; 3: 2039-2043.
20. Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130: 401-411.
21. McCrath D, Cerboni E, Hirsh A, Frumento RJ, Bennet-Guerrero E. Association of thrombelastography (MA) and thrombotic complications after major non-cardiac surgery. Anesth Analag 2003; 96: SCA13.
22. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
23. Bates ER, Lau WC, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation 2005; 111: 2557-2559.
24. Oqueli E, Hiscock M, Dick R. Clopidogrel resistance. Heart Lung Circ 2007; 16 Suppl 3: S17-S28.
25. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US. Clopidogrel loading with eptifibatide to arrest the reactivity of platelets study. Circulation 2005; 111: 1153-1159.
26. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
27. Abaci A, Yilmaz Y, Caliskan M, Bayram F, Cetin M, Unal A, et al. Effect of increasing doses of aspirin on platelet function as measured by PFA-100 inpatients with diabetes. Thromb Res 2005; 116: 465-470.
28. Gonzalez-Conejero R, Rivera J, Corral J, Acuna C, Guerrero JA, Vicente V. Biological assessment of aspirin efficacy on healthy individuals: heterogeneous response or aspirin failure? Stroke 2005; 36: 276-280.
29. Huyen AT, Sonia SA, Graeme JH, John WE. Aspirin resistance. Thromb Res 2007; 120: 337-346.
30. Stiles MK, Dabbous OH, Fox KA; GRACE investigators. Bleeding events with antithrombotic therapy in patients with unstable angina or non-ST-segment elevation myocardial infarction: insight from a large clinical practice registry (GRACE). Heart Lung Circ 2008; 17: 5-8.
31. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA, et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008; 29: 1057-1071.
32. Aronow HD, Steinhubl SR, Brennan DM, Berger PB, Topol EJ; CREDO Investigators. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J 2009; 157: 369-374.
33. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.